Haisco Pharmaceutical Group (SHE:002653) said China's drug regulator has accepted an investigational new drug application for an expanded indication of its HSK46575 tablets.
The application covers the use of HSK46575 in combination with olaparib or with docetaxel and prednisone for prostate cancer treatment, according to a Tuesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company rose 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments